$6.06
Today
as of Jul 22, 16:54 ET
Last 30 days
Recent Press Releases & News
ARS Pharmaceuticals (SPRY) Appoints Donn Casale As The New CEO
ARS Pharmaceuticals Names Donn Casale as CEO as Richard Lowenthal Departs
ARS Pharmaceuticals Announces CEO Succession
Overview
52-week range
$6.66
$19
0% of range
Avg surprise (last 3)
-9.1%
Avg reaction (last 2)
-7.9%
0% positive
Latest IV / EM
112%
EM ±25.6% · $5 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Fri May 15, 2026 | Mar/2026 | $-0.61 | $-0.53 | -15.1% | -74.3% | -6.5% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.52 | — | — | — | — | financials |
| Wed Aug 13, 2025 | Jun/2025 | $-0.46 | $-0.41 | -12.2% | — | — | earnings |
| Wed May 14, 2025 | Mar/2025 | $-0.35 | $-0.35 | 0.0% | — | -9.4% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.20 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.13 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.11 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.16 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.18 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Wed Aug 12, 2026 | Jun/2026 | OTHER | -$0.55 | -$0.46 | -19.6% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $23M | — | $33M | $16M | $8M | — | $2M | $500,000 |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-60M | — | $-53M | $-48M | $-37M | — | $-22M | $-15M |
| Net income | $-61M | — | $-51M | $-45M | $-34M | — | $-19M | $-13M |
| EPS (diluted) | $-0.61 | — | $-0.52 | $-0.46 | $-0.35 | — | $-0.20 | $-0.13 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $24M | $41M | $60M | $52M | $40M | $51M | $40M | $37M |
| Inventory | $32M | $31M | $21M | $22M | $7M | $11M | $715,000 | — |
| Total current assets | $245M | $285M | $339M | $281M | $304M | $334M | $209M | $221M |
| Total assets | $288M | $328M | $373M | $313M | $327M | $351M | $218M | $222M |
| Long-term debt | $97M | $96M | $96M | — | — | $0 | — | — |
| Total liabilities | $226M | $213M | $225M | $121M | $98M | $94M | $17M | $7M |
| Total equity | $61M | $114M | $148M | $192M | $229M | $257M | $201M | $215M |